CLIN CHEM:开发用于检测人类血清中疾病特异性外泌体数量的高灵敏度装置

2018-10-29 MedSci MedSci原创

虽然血液中的循环外泌体在癌症发生和进展中起着至关重要的作用,但是对外泌体进行量化的困难阻碍了其在临床试验中可靠的应用。通过将纳米珠的特性与光技术相结合,研究人员开发了一种名为ExoCounter的新型装置,用于鉴定各种类型癌症患者血清中外泌体的确切数量。 该系统将单个外泌体捕获在涂有针对外来体表面抗原的抗体的光盘的凹槽中。用抗体偶联的磁性纳米珠标记捕获的外泌体,并用光盘驱动器计数标记的外泌体

虽然血液中的循环外泌体在癌症发生和进展中起着至关重要的作用,但是对外泌体进行量化的困难阻碍了其在临床试验中可靠的应用。通过将纳米珠的特性与光技术相结合,研究人员开发了一种名为ExoCounter的新型装置,用于鉴定各种类型癌症患者血清中外泌体的确切数量。

该系统将单个外泌体捕获在涂有针对外来体表面抗原的抗体的光盘的凹槽中。用抗体偶联的磁性纳米珠标记捕获的外泌体,并用光盘驱动器计数标记的外泌体的数目。

研究人员发现ExoCounter可以检测来自细胞或人血清的特定外泌体,无需任何富集程序。该系统的检测灵敏度和线性度均高于常规检测方法,如ELISA或流式细胞仪。除了普遍存在的外来体标志物CD9CD63之外,癌症相关抗原CD147,癌胚抗原和人表皮生长因子受体2HER2)也用于定量癌细胞系衍生的外泌体。此外,对血清样品的横截面队列的分析显示,与健康个体和患有非癌症疾病的患者相比,乳腺癌卵巢癌患者中HER2阳性外泌体显著增加。

研究表明ExoCounter系统在直接检测细胞培养和人血清中的外泌体方面表现出较高性能。该方法可以实现对液体活组织检查的可靠分析。

原始出处:

Yasuaki Kabe, Makoto Suematsu, Satoshi Sakamoto,Development of a Highly Sensitive Device for Counting the Number of Disease-Specific Exosomes in Human Sera

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775930, encodeId=e82d1e75930e8, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Wed Sep 04 12:24:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899247, encodeId=ff70189924e56, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 22 20:24:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350906, encodeId=ece13509068a, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Oct 30 05:52:12 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350891, encodeId=a65435089164, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 29 22:51:50 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2019-09-04 respect
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775930, encodeId=e82d1e75930e8, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Wed Sep 04 12:24:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899247, encodeId=ff70189924e56, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 22 20:24:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350906, encodeId=ece13509068a, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Oct 30 05:52:12 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350891, encodeId=a65435089164, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 29 22:51:50 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775930, encodeId=e82d1e75930e8, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Wed Sep 04 12:24:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899247, encodeId=ff70189924e56, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 22 20:24:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350906, encodeId=ece13509068a, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Oct 30 05:52:12 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350891, encodeId=a65435089164, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 29 22:51:50 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-30 yjs木玉

    好好好好好好好好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1775930, encodeId=e82d1e75930e8, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Wed Sep 04 12:24:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899247, encodeId=ff70189924e56, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Jul 22 20:24:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350906, encodeId=ece13509068a, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Oct 30 05:52:12 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350891, encodeId=a65435089164, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Oct 29 22:51:50 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-29 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

Oncogene:外泌体介导的lncRUNX2-AS1有助于成骨

多发性骨髓瘤(MM)的特征是间充质干细胞(MSCs)的成骨能力降低。癌细胞和癌症基质细胞之间的交流是肿瘤进展的主要因素。了解骨髓瘤-基质的相互作用对于开发可逆转骨疾病的有效策略至关重要。本研究中,我们发现骨髓瘤细胞中的生物活性lncRNA RUNX2-AS1可以包装到外泌体中并传递给MSCs,从而抑制MSCs的成骨。来自RUNX2反义链的RUNX2-AS1在源自MM患者(MM-MSC)的MSCs中

PNAS:香港中文大学深圳研究所黄聿研究组揭示了血清外泌体糖尿病方面的重要作用

2018年7月2日,香港中文大学深圳研究所黄聿研究组等人在PNSA上在线发表了题为“Serum exosomes mediate delivery of arginase 1 as a novel mechanism for endothelial dysfunction in diabetes”的文章,该文章表明SExos将精氨酸酶1蛋白质递送至内皮细胞,替代了糖尿病内皮功能障碍发展过程中的细胞

Sci Rep:尿液外泌体和游离DNA检测膀胱尿路上皮癌的体细胞变异和拷贝数变异

尿路上皮膀胱癌(UBC)可以通过很多的遗传变异来鉴定。来自尿液的DNA检测是一种非常有前景的用来进行泌尿系肿瘤液体活检的方法。最近,有研究人员评估了尿液中游离DNA(cfDNA)和外泌体DNA(exoDNA)作为UBC液体活检的一种来源的有效性。研究包括了9名患者,这些患者因UBC经历了外科手术,并且对他们的肿瘤样本、匹配的尿液cfDNA和exoDNA进行了基因组分析。研究发现,在6名患者中发现了

Nature:免疫治疗失败竟是因为外泌体!液态活检重大新发现!

最近,由宾夕法尼亚大学文理学院生物学系郭巍教授、宾夕法尼亚大学病理学和实验室医学徐小威教授通力合作,8月8日最新发表在《自然》杂志上的研究,为癌症如何在全身对抗免疫系统带来了颠覆性的认识,其中关键因素居然在于外泌体!

外泌体介导的速效救心丸在缺血损伤心肌中的保护作用

目前对于AMI的治疗(药物、溶栓及介入等)旨在保留剩余的心肌细胞并降低与AMI病理学后果相关的发病率和病死率,即使早期进行血运重建也只可能挽救约50%的梗死面积。因此,IHD再生疗法是新近的研究热点之一。

Diabetes:血浆外泌体可通过激活经典补体信号通路促进糖尿病视网膜病变的微血管损伤

糖尿病视网膜病变(DR)是糖尿病的微血管并发症,是劳动年龄的成年人视力下降的主要原因。近期有研究表明补体系统在血管损伤发展和DR进展中也发挥一定作用。但是,补体系统激活在DR中的作用尚不是十分明确。外泌体,分泌到细胞外环境的小囊泡,在血浆中含有大量补体蛋白,提示其可能参与导致与DR相关的血管损伤。研究人员证实血浆中充满IgG的外泌体可激活经典补体通路,而在糖尿病患者血浆中,这类外泌体量增多。而且,